Comparison
1p35 2 Microdeletion Syndrome vs 11q22 2q22 3 Microdeletion Syndrome C5680062
Clinical comparison between 1p35 2 Microdeletion Syndrome and 11q22 2q22 3 Microdeletion Syndrome for differential diagnosis and treatment planning.
6 comparison axes
Onset
1p35 2 Microdeletion Syndrome
0-null
11q22 2q22 3 Microdeletion Syndrome C5680062
0-null
Onset patterns differ
Severity
1p35 2 Microdeletion Syndrome
severe
11q22 2q22 3 Microdeletion Syndrome C5680062
moderate
Different severity levels
Chronic
1p35 2 Microdeletion Syndrome
Chronic
11q22 2q22 3 Microdeletion Syndrome C5680062
Chronic
Differing course
Communicable
1p35 2 Microdeletion Syndrome
No
11q22 2q22 3 Microdeletion Syndrome C5680062
No
Different transmission
Body System
1p35 2 Microdeletion Syndrome
congenital
11q22 2q22 3 Microdeletion Syndrome C5680062
congenital
Same/different system
Category
1p35 2 Microdeletion Syndrome
rare-disease
11q22 2q22 3 Microdeletion Syndrome C5680062
genetic
Different category
Bottom line
1p35-2-microdeletion-syndrome-C5679992 and 11q22-2q22-3-microdeletion-syndrome-C5680062 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 1p35 2 Microdeletion Syndrome | 11q22 2q22 3 Microdeletion Syndrome C5680062 | Discriminating power |
|---|---|---|---|
| Chromosomal locus | Reported deletion involving 1p35.2; phenotype details are not supplied. | Reported deletion involving 11q22.2–q22.3; developmental effects are possible but unspecified. | High |
| Severity label | Supplied axis labels it severe, but this is not clinical proof. | Supplied data label it moderate, with supportive symptom management. | Moderate |
| Clinical features | Specific symptoms, complications, and course are not established here. | Source notes varied health concerns without listing definitive features. | Low |
When to favor each condition
Choose 1p35 2 Microdeletion Syndrome when
A validated test identifies a 1p35.2 microdeletion.
The chromosomal locus is the clearest supplied distinction.
High
Records use the severe rare-disease classification for this concept.
That label comes from supplied axes, not measured outcomes.
Moderate
11q22.2–q22.3 deletion has been excluded.
Absence of the right-sided locus supports considering the left concept.
High
Choose 11q22 2q22 3 Microdeletion Syndrome C5680062 when
A validated test identifies an 11q22.2–q22.3 microdeletion.
The locus directly matches the right-sided concept.
High
Coding or review concerns a moderate congenital anomaly, such as Q89.9 context.
This aligns with supplied classification, not a specific phenotype.
Moderate
Care is planned around unspecified developmental or health concerns.
The source supports supportive, symptom-focused management.
Moderate
How key tests differ
| Test | 1p35 2 Microdeletion Syndrome | 11q22 2q22 3 Microdeletion Syndrome C5680062 | Interpretation |
|---|---|---|---|
| Chromosomal microarray | May show copy-number loss at 1p35.2. | May show copy-number loss at 11q22.2–q22.3. | Locus and breakpoints distinguish the concepts; clinical correlation is required. |
| Standard karyotype | A small deletion may not be visible. | A small deletion may not be visible. | A normal karyotype does not exclude either microdeletion. |
| Parental genetic studies | Inheritance pattern is not established in the source. | Inheritance pattern is not established in the source. | Results may clarify origin but do not define prognosis. |
Prognosis comparison
1p35 2 Microdeletion Syndrome
- Outcome
- Long-term outcome is not established.
- Factors
- Severe and chronic labels are supplied, but prognostic factors are unknown.
11q22 2q22 3 Microdeletion Syndrome C5680062
- Outcome
- Outcome is not established; supportive care addresses identified needs.
- Factors
- Moderate severity is supplied, while specific predictors are unknown.
Time frame: Congenital and potentially lifelong; exact milestones are not established.
Deleted locus, individual findings, and clinical assessment matter; no comparative survival claim is supported.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental concerns | Not specifically established in the supplied data. Development may be affected, but features are unspecified. Do not infer a particular developmental profile from these labels. |
| Organ or health complications | No definitive complication list is supplied. Various health concerns are mentioned without specifics. Complication risk should be assessed individually by clinicians. |
| Long-term medical needs | A chronic congenital course is indicated, without details. A chronic course with supportive care is described. Neither source establishes mortality or treatment intensity. |
Patient education highlights
- HighGenetic confirmation
The named syndromes are distinguished primarily by the deleted chromosomal region, confirmed through appropriate genetic testing.
- HighUncertain features
Available information does not establish exact symptoms, laboratory cutoffs, prevalence, or outcomes for either condition.
- MediumSupportive care
Management is individualized and supportive; medication doses or specific treatments are not established here.